Risk factors of SARS-CoV-2 infection in cancer patients pre- and post-vaccination

Background Severe complications from COVID-19 and poor responses to SARS-CoV-2 vaccination were commonly reported in cancer patients compared to those without cancer. Therefore, the identification of predisposing factors to SARS-CoV-2 infection in cancer patients would assist in the prevention of COVID-19 and improve vaccination strategies. The literature lacks reports on this topic from the Kingdom of Saudi Arabia (KSA). Therefore, we studied clinical and laboratory data of 139 cancer patients from King Abdulaziz Medical City, Riyadh, KSA. Methods The cancer patients fall into three categories; (i) uninfected with SARS-CoV-2 pre-vaccination and remained uninfected post-vaccination (control group; n = 114; 81%), (ii) pre-vaccination infected group (n = 16; 11%), or (iii) post-vaccination infected group (n = 9; 6%). Next, the clinical and lab data of the three groups of patients were investigated. Results Comorbidity factors like diabetes and hemodialysis were associated with the risk of infection in cancer patients before the vaccination (p<0.05). In contrast to breast cancer, papillary thyroid cancer was more prevalent in the infected patients pre- and post-vaccination (p<0.05). Pre-vaccination infected group had earlier cancer stages compared with the control group (p = 0.01). On the other hand, combined therapy was less commonly administrated to the infected groups versus the control group (p<0.05). Neutrophil to lymphocyte ratio was lower in the post-vaccination infected group compared to the control group (p = 0.01). Conclusion Collectively, this is the first study from KSA to report potential risk factors of SARS-CoV-2 infection in cancer patients pre- and post-vaccination. Further investigations on these risk factors in a larger cohort are worthwhile to draw a definitive conclusion about their roles in predisposing cancer patients to the infection.

[1]  M. Preusser,et al.  SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria , 2022, Wiener klinische Wochenschrift.

[2]  K. Decker,et al.  Evaluating the impact of the COVID-19 pandemic on cancer screening in a central Canadian province , 2022, Preventive Medicine.

[3]  G. Siasos,et al.  Charting the Unknown Association of COVID-19 with Thyroid Cancer, Focusing on Differentiated Thyroid Cancer: A Call for Caution , 2021, Cancers.

[4]  Jin-fang Xu,et al.  Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines , 2021, Cell discovery.

[5]  S. Mir,et al.  Haematological and radiological-based prognostic markers of COVID-19 , 2021, Journal of Infection and Public Health.

[6]  N. Arber,et al.  Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients , 2021, Journal of the National Cancer Institute.

[7]  S. Olatunji,et al.  Comorbidities and Risk Factors for Severe Outcomes in COVID-19 Patients in Saudi Arabia: A Retrospective Cohort Study , 2021, Journal of multidisciplinary healthcare.

[8]  T. Spektor,et al.  Response to mRNA vaccination for COVID-19 among patients with multiple myeloma , 2021, Leukemia.

[9]  S. Wen,et al.  One‐year mortality and consequences of COVID‐19 in cancer patients: A cohort study , 2021, IUBMB life.

[10]  E. Sawyer,et al.  COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients , 2021, Cancers.

[11]  E. Chamorey,et al.  Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors , 2021, Annals of Oncology.

[12]  M. Malim,et al.  Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.

[13]  M. Dimopoulos,et al.  Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose , 2021, Blood.

[14]  M. Rotondi,et al.  Thyroid sequelae of COVID-19: a systematic review of reviews , 2021, Reviews in Endocrine and Metabolic Disorders.

[15]  Mohammed Aljuaid,et al.  Cardiovascular Risk Factors Among Patients Infected with COVID-19 in Saudi Arabia , 2021, Vascular health and risk management.

[16]  G. Ursin,et al.  COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway , 2021, Frontiers in Oncology.

[17]  N. Fernández,et al.  Early prediction keys for COVID-19 cases progression: A meta-analysis , 2021, Journal of Infection and Public Health.

[18]  N. Al-Daghri,et al.  Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study , 2020, Cardiovascular Diabetology.

[19]  H. Tayebi-Khosroshahi,et al.  Risk Factors for COVID-19. , 2020, Le infezioni in medicina.

[20]  N. Al-Daghri,et al.  Prevalence of diabetes, management and outcomes among Covid-19 adult patients admitted in a specialized tertiary hospital in Riyadh, Saudi Arabia , 2020, Diabetes Research and Clinical Practice.

[21]  Nathanael R. Fillmore,et al.  Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study , 2020, Journal of the National Cancer Institute.

[22]  C. Akdis,et al.  Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.

[23]  D. Kerr,et al.  COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study , 2020, The Lancet Oncology.

[24]  P. Lovat,et al.  Reduction in skin cancer diagnoses in the UK during the COVID‐19 pandemic , 2020, Clinical and experimental dermatology.

[25]  F. Pitoia,et al.  Thyroid cancer in the Era of COVID-19 , 2020, Endocrine.

[26]  R. Gale,et al.  Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission , 2020, Leukemia.

[27]  E. Robilotti,et al.  Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.

[28]  Nazar Zaki,et al.  Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[29]  D. Ma,et al.  Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis , 2020, Journal of Hematology & Oncology.

[30]  A. Assiri,et al.  Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study , 2020, Journal of Infection and Public Health.

[31]  Sun-Hee Park,et al.  Outcomes of COVID-19 among Patients on In-Center Hemodialysis: An Experience from the Epicenter in South Korea , 2020, Journal of clinical medicine.

[32]  Zhiquan Hu,et al.  Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[33]  Jun Yu Li,et al.  Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[34]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[35]  M. Gleeson,et al.  Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London , 2020, Frontiers in Oncology.

[36]  H. Alwafi,et al.  Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia , 2020, medRxiv.

[37]  A. Vincent-Salomon,et al.  COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area , 2020, Breast Cancer Research.

[38]  S. Kalnicki,et al.  Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System , 2020, Cancer discovery.

[39]  E. Rodríguez‐Suárez,et al.  High prevalence of asymptomatic COVID-19 in hemodialysis. Daily learning during first month of COVID-19 pandemic , 2020, Nefrología (English Edition).

[40]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[41]  Geltrude Mingrone,et al.  Practical recommendations for the management of diabetes in patients with COVID-19 , 2020, The Lancet Diabetes & Endocrinology.

[42]  O. Al-Quteimat,et al.  The Impact of the COVID-19 Pandemic on Cancer Patients , 2020, American journal of clinical oncology.

[43]  C. Booth,et al.  Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic , 2020, Nature Reviews Clinical Oncology.

[44]  T. Ikizler COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do? , 2020, American Journal of Kidney Diseases.

[45]  Rui Ji,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[46]  Ritesh Gupta,et al.  Clinical considerations for patients with diabetes in times of COVID-19 epidemic , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[47]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[48]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[49]  A. Fard-Esfahani,et al.  Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma , 2014, Nuclear medicine communications.

[50]  Stephanie L. Lee Complications of radioactive iodine treatment of thyroid carcinoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[51]  S. Larson,et al.  Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. , 2009, Thyroid : official journal of the American Thyroid Association.

[52]  S. Chow Side Effects of High-dose Radioactive Iodine for Ablation or Treatment of Differentiated Thyroid Carcinoma , 2005 .